Floatz logo

23me-00610

Neuroendocrine Tumors

23andMe, Inc.Phase 1/2Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
73/ 100

Competitive context

61 Active assets in the Neuroendocrine Tumors cohort.

Asset / SponsorPhaseRating
Irinotecan
First Affiliated Hospital Xi'an Jiaotong University
Phase 4BB
Bms-907351
Fox Chase Cancer Center
Phase 3BB
Eloxatin
ITM Solucin GmbH
Phase 3BB
FLUOROURACILUM
ITM Solucin GmbH
Phase 3BB
Pasireotide
RECORDATI GROUP
Phase 4BB

View all 50 →

Same molecule, other indications

23me-00610 is also rated in:

Cancer With A High Tumor Mutational BurdenDormant
CCC
Indicative ·
48 / 100
View asset →
MSI-H CancerDormant
CC
Indicative ·
47 / 100
View asset →
primary peritoneal carcinomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →